All Stories

  1. A Systematic Review and a VigiBase Study of Accidental Clozapine Intoxications in Children and Adolescents
  2. Reply to “Beyond Hypersalivation: Protecting Older Clozapine Users through Better Recognition of Swallowing Vulnerability”
  3. VigiBase suggests that the number of deaths by suicide in adolescents with schizophrenia as a result of not taking clozapine may be much higher than the number of deaths from agranulocytosis after taking clozapine
  4. When Doing Nothing Feels Safer: A Multilevel Framework for Therapeutic Inertia in Psychiatry
  5. Comparative Pharmacovigilance Analysis of Pulmonary Embolism Across Antipsychotics in VigiBase
  6. Prescribing Under Uncertainty: The Hidden Psychology of Psychiatric Decision-Making
  7. When Doing Nothing Feels Safer: Therapeutic Inertia and Risk Perception in Psychiatry
  8. Reviewer recommendations and editorial outcomes in peer review: a longitudinal analysis of agreement and disagreement across review rounds
  9. Reply to beyond fatality signals: reconsidering clozapine safety through severe gastrointestinal hypomotility and real-world clinical complexity
  10. Changing Your Perspective on Fatal Outcomes in Clozapine-treated patients.
  11. Psychiatry Between Ethics and Activism: Rethinking Professional Authority and Scientific Integrity in Contemporary Mental Healthcare
  12. Autonomy Under Uncertainty: Are We Overestimating Decision-Making Capacity in Psychiatric End-of-Life Contexts?
  13. Beyond Consensus, Beyond Closure: Rethinking Relapse in Schizophrenia Through a Multidimensional Lens
  14. Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia
  15. Digital Adverse Events: Rethinking Psychopathology and Public Mental Health in the Era of Human–AI Interaction
  16. Reclaiming Pharmacovigilance: Bridging the Evidence–Practice Gap in Psychopharmacology
  17. Co-Created Digital Pretherapy Psychoeducation for Outpatients in Specialized Mental Health Care: Usability Evaluation and Patient Satisfaction Study
  18. A Study in VigiBase of Clozapine Fatal Outcomes in 7,874 Middle-Aged versus 4,380 Young Adults
  19. A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase
  20. Psychiatry is not the science of unhappiness
  21. Insomnio: enfoque clínico y terapéutico
  22. Clozapine and Suicide in VigiBase
  23. Fatal Outcomes in Use of Clozapine
  24. The Crisis of Meaning in Aging and the Expansion of Medically Unjustified Euthanasia: A Psychiatric Imperative
  25. Letter to the Editor regarding: “Towards a name change of schizophrenia: positive and negative symptoms disorder (PND)”
  26. On dosing equity, scientific responsibility, and what remains unsaid
  27. Clozapine and Regulatory Inertia: Revisiting Evidence, Risks, and Reform
  28. Co-Created Digital Pretherapy Psychoeducation for Outpatients in Specialized Mental Health Care: Usability Evaluation and Patient Satisfaction Study (Preprint)
  29. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature
  30. Perceived Stress and Clinical Insomnia in Primary Care: Associations with Lifestyle and Medication Use
  31. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I
  32. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
  33. The Sleep Expectation–Reality Gap: Exploring Discrepancies Between Perceived and Ideal Sleep Duration in Primary Care Patients
  34. Reflections on the Potential and Risks of AI for Scientific Article Writing after the AI Endorsement by Some Scientific Publishers: Focusing on Scopus AI
  35. Clozapine pharmacovigilance in Croatia: underreporting of specific adverse drug reactions and excellent reporting of suicide attempts
  36. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
  37. A case of recurrent priapism during prolonged clozapine administration
  38. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data
  39. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety
  40. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature
  41. Exploring the Relationship Between Psychological Constructs and Decision-Making Preferences in Psychiatric Outpatients
  42. Implications of psychological reactance for clinical practice in psychiatry including a systematic review.
  43. Investigating in VigiBase® over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia
  44. Psychoeducational group interventions for adults diagnosed with attention-deficit/ hyperactivity disorder: a scoping review of feasibility, acceptability, and outcome measures
  45. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK
  46. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database
  47. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance
  48. Will ChatGPT3 Substitute for us as Clozapine Experts?
  49. Guía internacional Para una dosificación más Segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la Proteína C Reactiva y los niveles de clozapina
  50. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance
  51. Psychiatric Patients’ Perceived Health Control and Reactance: Implications for Medication Adherence
  52. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients
  53. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)
  54. Escaping the Long Shadow Cast by Agranulocytosis
  55. Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in VigiBase
  56. NURSING STUDENT’S VIEWS ON THE DUTY OF CARE: A CROSS-SECTIONAL STUDY IN TWO COUNTRIES
  57. Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review
  58. Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries
  59. Clozapine-induced myocarditis in Russia: Animal studies but no clinical studies
  60. Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase
  61. Psychometric Properties of the WHO-5 Well-Being Index among Nurses during the COVID-19 Pandemic: A Cross-Sectional Study in Three Countries
  62. Clozapine and the risk of haematological malignancies
  63. An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine
  64. Evaluating the Effect of a Telepsychiatry Educational Program on the Awareness, Knowledge, Attitude, and Skills of Telepsychiatry Among Spanish Psychiatrists during COVID-19 Pandemic
  65. An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s
  66. The duty to care and nurses' well-being during a pandemic
  67. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase
  68. Promoting safer clozapine dosing in the Americas
  69. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
  70. The Mediating Role of Resilience in the Relationship between Perceived Stress and Mental Health
  71. Miocarditis inducida por la clozapina: estudios animales pero no clínicos
  72. Clozapine-associated myocarditis in the World Health Organization’s pharmacovigilance database: Focus on reports from various countries
  73. Clinimetric Criteria for Patient-Reported Outcome Measures
  74. Exploring patterns in psychiatric outpatients’ preferences for involvement in decision-making: a latent class analysis approach
  75. Effect of necessity‐concern framework and polypharmacy on treatment adherence in psychiatric patients. Comparing an Argentinian with a Spanish sample
  76. An update on the complex relationship between clozapine and pneumonia
  77. Effects of a peer co-facilitated educational programme for parents of children with ADHD: a feasibility randomised controlled trial protocol
  78. Self-Report for Measuring and Predicting Medication Adherence: Experts’ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics
  79. Patient-reported well-being: psychometric properties of the world health organization well-being index in specialised community mental health settings
  80. Assessment of shared decision-making in community mental health care: Validation of the CollaboRATE
  81. Psychometric properties of the Five‐item World Health Organization Well‐being Index used in mental health services: Protocol for a systematic review
  82. The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase
  83. A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology
  84. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics
  85. The necessity‐concern framework in the assessment of treatment adherence of psychiatric patients and the role of polypharmacy in a Spanish sample
  86. Data From the World Health Organization’s Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions
  87. Development and validation of the Patient’s Health Belief Questionnaire on Psychiatric Treatment
  88. Effectiveness and cost-effectiveness of a multicomponent intervention to improve medication adherence in people with depressive disorders - MAPDep: a study protocol for a cluster randomized controlled trial
  89. Ethnopsychopharmacology study of patients' beliefs regarding concerns about and necessity of taking psychiatric medications
  90. A Clinimetric Approach for Improving the Measurement of Pharmacophobia with Replication in Two Other Samples
  91. Meet Our Editorial Board Member
  92. Predictive validity of the Sidorkiewicz instrument in Spanish: Assessing individual drug adherence in psychiatric patients
  93. Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: a comparison among outpatient samples recruited in Spain, Argentina, and Venezuela
  94. The Art of Pharmacotherapy
  95. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach
  96. Reviving Research on Medication Attitudes for Improving Pharmacotherapy: Focusing on Adherence
  97. Are Acceptance and Skepticism Determinant Factors for Adherence to Drug Treatment in Psychiatric Patients?
  98. Validity of the Control Preferences Scale in patients with emotional disorders
  99. Perceived Health Control
  100. Treatment-related decisional conflict in patients with depressive and anxious disorders
  101. The effect of a brief educational programme added to mental health treatment to improve patient activation: A randomized controlled trial in community mental health centres
  102. Preferencias por las decisiones compartidas en pacientes con depresión
  103. Métodos de valoración de la adherencia al tratamiento psiquiátrico en la práctica clínica
  104. Validation of the General Self-Efficacy Scale in psychiatric outpatient care
  105. Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence
  106. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting
  107. What Do Psychiatric Patients Believe Regarding Where Control Over Their Illness Lies?
  108. The relationship of psychological reactance, health locus of control and sense of self-efficacy with adherence to treatment in psychiatric outpatients with depression
  109. To what extent is treatment adherence of psychiatric patients influenced by their participation in shared decision making?
  110. Psychological reactance in psychiatric patients: Examining the dimensionality and correlates of the Hong Psychological Reactance Scale in a large clinical sample
  111. Psychiatric patients’ preferences and experiences in clinical decision-making: Examining concordance and correlates of patients’ preferences
  112. Validation of the Spanish version of the 9-item Shared Decision-Making Questionnaire
  113. Preferences for participation in shared decision making of psychiatric outpatients with affective disorders
  114. To what extent psychiatric patients feel involved in decision making about their mental health care? Relationships with socio-demographic, clinical, and psychological variables
  115. Risk factors for non-adherence to antidepressant treatment in patients with mood disorders
  116. Shared decision making in psychiatric practice and the primary care setting is unique, as measured using a 9-item Shared Decision Making Questionnaire (SDM-Q-9)
  117. Sociodemographic and clinical predictors of compliance with antidepressants for depressive disorders: systematic review of observational studies
  118. Psychiatric outpatients' self-reported adherence versus psychiatrists' impressions on adherence in affective disorders
  119. Estrategias de manejo de los antidepresivos desde la perspectiva de los pacientes: luchando interna y externamente
  120. Attitudes toward concordance in psychiatry: a comparative, cross-sectional study of psychiatric patients and mental health professionals
  121. Psychiatric patients’ attitudes towards concordance and shared decision making
  122. Mental health professionals' attitudes to partnership in medicine taking: a validation study of the Leeds Attitude to Concordance Scale II
  123. ¿Están relacionadas la obesidad y otras comorbilidades físicas con la enfermedad mental?
  124. Editorial [Hot Topic: Compliance, Adherence and Concordance in Medicine Taking of Psychiatric Patients (Guest Editor: Carlos De las Cuevas)]
  125. Towards a Clarification of Terminology in Medicine Taking Behavior: Compliance, Adherence and Concordance are Related Although Different Terms with Different Uses
  126. Adaptation and validation study of the Beliefs about Medicines Questionnaire in psychiatric outpatients in a community mental health setting
  127. Antidepressant Use in Early Pregnancy
  128. Lithium Use During Early, Late Pregnancy, and Breastfeeding
  129. Psychomotor performance and fitness to drive: The influence of psychiatric disease and its pharmacological treatment
  130. Versión española consensuada de la Severity of Dependence Scale (SDS)
  131. Fitness to Drive of Psychiatric Patients
  132. Attitudes toward psychiatric drug treatment: the experience of being treated
  133. Duloxetine-Induced Excessive Disturbing and Disabling Yawning
  134. Are psychotropics drugs used in pregnancy?
  135. Randomized Clinical Trial of Telepsychiatry through Videoconference versus Face-to-Face Conventional Psychiatric Treatment
  136. Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy
  137. Polypsychopharmacy
  138. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis
  139. Telepsychiatry: Psychiatric consultation through videoconference patients' perception and satisfaction
  140. Telepsychiatry: Psychiatric consultation through videoconference clinical results
  141. Polypharmacy in psychiatric practice in the Canary Islands
  142. Do therapeutic indications of antidepressants change from one year to another?
  143. Telepsychiatry in the Canary Islands: user acceptance and satisfaction
  144. Telepsiquiatría: utopía o realidad asistencial
  145. Benzodiazepines: more "behavioural" addiction than dependence
  146. Burnout en los profesionales de la atención a las drogodependencias
  147. Telepsiquiatría: utopía o realidad asistencial
  148. Variations in antidepressant prescribing practice: clinical need or market influences?
  149. The Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence: SDS validation study
  150. Benzodiazepine prescription is different in the public and private sectors
  151. Prescribed daily doses and ‘risk factors’ associated with the use of benzodiazepines in primary care
  152. Benzodiazepine audit in primary care
  153. PSYCHOPATHOLOGICAL PROFILE IN ANXIETY DISORDERS
  154. INSOMNIA AND AFFECTIVE DISORDERS